Table 2

Patients' features

c.35 G>A KRAS mutant

Other KRAS mutant

KRAS wild-type


Total Number (%)

Total Number (%)

Total Number (%)


Number of patients

15 (25)

13 (22)

31 (53)

Sex

male/female

11/4

5/8

21/10

Age, years

median

67

63

64

range

51 to 73

48 to 71

42 to 73

≥65 years

8 (53)

5 (38)

13 (42)

WHO Performance Status

0

13 (87)

13 (100)

28 (90)

1-2

2 (13)

-

3 (10)

Metastatic disease

metachronous

5 (33)

2 (15)

10 (32)

synchronous

10 (67)

11 (85)

21 (68)

Primary tumor

colon

10 (67)

10 (77)

14 (45)

rectum

5 (33)

3 (23)

17 (55)

Sites of metastases

liver

12 (80)

8 (61.5)

19 (61)

lung

3 (20)

2 (15)

7 (23)

lymph nodes

4 (27)

4 (31)

10 (32)

local

2 (13)

1 (8)

6 (19)

other

4 (27)

2 (15)

2 (6)

Number of involved sites

1

8 (53)

9 (69)

17 (55)

≥2

7 (47)

4 (31)

14 (45)

Single metastatic sites

liver-limited

6 (40)

7 (54)

12 (39)

other than liver

2 (13)

2 (15)

7 (22)

lung

1 (6.5)

1 (8)

2 (6)

lymph nodes

-

1 (8)

2 (6)

Local

1 (6.5)

-

3 (10)

multiple metastatic site

7 (47)

4 (31)

12 (39)

Liver metastases

single

2 (13)

1 (8)

8 (26)

multiple

10 (67)

7 (54)

11 (35)

Previous adjuvant chemotherapy:

1 (6.5)

1 (8)

6 (19)

FA/5-FU bolus

-

-

3 (10)

Capecitabine

-

-

-

FOLFOX4

1 (6.5)

1 (8)

2 (6)

XelOx

-

-

1 (3)

Previous radiotherapy:

1 (6.5)

-

4 (13)

RT alone

-

-

-

RT+CT (5-FU c.i.)

-

-

2 (6)

RT+CT (XELOX)

1 (6.5)

-

2 (6)


c.i., continuous infusion; WHO, World Health Organization.

Bruera et al. BMC Medicine 2013 11:59   doi:10.1186/1741-7015-11-59

Open Data